Having trouble accessing articles? Reset your cache.

Digital health guidances clarify which techs FDA will review

A pair of guidances released by FDA on Thursday clarifies what digital health technologies do and do not fall under the agency’s review process.

FDA revised draft guidance on clinical decision support software after stakeholders asked that the agency consider a risk-based categorization of software products based on the risk to

Read the full 515 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers